Imunon, Inc. Files 8-K Report
Ticker: IMNN · Form: 8-K · Filed: Sep 3, 2024 · CIK: 749647
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory-update
TL;DR
IMUN filed an 8-K, likely standard updates, no major news.
AI Summary
On September 3, 2024, Imunon, Inc. filed an 8-K report detailing "Other Events" and "Financial Statements and Exhibits." The filing does not disclose specific new events or financial figures but serves as a notification of these items being reported.
Why It Matters
This filing indicates that Imunon, Inc. is providing updates on its operations and financial status to the SEC, which is standard practice for public companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain information that suggests an immediate change in risk for the company.
Key Players & Entities
- Imunon, Inc. (company) — Registrant
- September 3, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-15911 (commission_file_number) — SEC File Number
- 52-1256615 (irs_number) — IRS Employer Identification No.
- 997 Lenox Drive , Suite 100 , Lawrenceville , NJ 08648-2311 (address) — Principal Executive Office Address
FAQ
What specific "Other Events" are being reported by Imunon, Inc. in this 8-K filing?
The filing lists "Other Events" as an item, but the provided text does not detail the specific nature of these events.
What "Financial Statements and Exhibits" are included with this 8-K filing?
The filing indicates that "Financial Statements and Exhibits" are part of the report, but the specific contents are not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on September 3, 2024.
What is Imunon, Inc.'s state of incorporation?
Imunon, Inc. is incorporated in Delaware.
What is the principal business address of Imunon, Inc.?
The principal business address of Imunon, Inc. is 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648-2311.
Filing Stats: 600 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-09-03 08:10:39
Key Financial Figures
- $0.01 — ge on which registered) Common stock, $0.01 par value IMNN The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex5-1.htm (EX-5.1) — 11KB
- ex5-1_001.jpg (GRAPHIC) — 61KB
- 0001493152-24-034716.txt ( ) — 310KB
- imnn-20240903.xsd (EX-101.SCH) — 3KB
- imnn-20240903_lab.xml (EX-101.LAB) — 33KB
- imnn-20240903_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMUNON, INC. Date: September 3, 2024 /s/ David Gaiero David Gaiero Chief Financial Officer